US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

REIN THERAPEUTICS INC

1.32

+0.02001.54%

Post-market: 1.330.0100+0.76%19:39 EDT

Volume:61.52K

Turnover:80.56K

Market Cap:31.71M

PE:-0.50

High:1.35

Open:1.30

Low:1.24

Close:1.30

52wk High:4.40

52wk Low:1.04

Shares:24.03M

Float Shares:20.03M

Volume Ratio:0.34

T/O Rate:0.31%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-2.6428

EPS(LYR):-3.5054

ROE:-79.38%

ROA:-18.24%

PB:10.54

PE(LYR):-0.38

Loading ...

Overview Company News Filings

Rein receives European regulatory approval to initiate Phase 2 trial of LTI-03

Rein Therapeutics receives EMA approval to begin Phase 2 trial of LTI03 for idiopathic pulmonary fibrosis in Europe

Rein Therapeutics Receives European Regulatory Approval to Initiate Phase 2 Trial of Lti-03 in Idiopathic Pulmonary Fibrosis

THOMSON REUTERS

Rein Therapeutics Inc. Files Initial Statement of Beneficial Ownership by Voss Capital, LP

Rein Therapeutics Inc - Receives Communication From FDA on September 16, 2025 - SEC Filing

THOMSON REUTERS

Rein Therapeutics - FDA Recommends Co to Submit Crl Addressing Amended Study Reports & Justification - SEC Filing

THOMSON REUTERS

Rein Therapeutics Inc. : H.c. Wainwright Initiates Coverage With Buy Rating and Target Price $10

THOMSON REUTERS

Rein Therapeutics announces publication of data on LTI-03 in IPF

Rein Therapeutics Announces Publication of New Translational Data in iScience on Company’s Novel Therapy for Idiopathic Pulmonary Fibrosis

Rein Therapeutics Secures $1 Million Pre-Paid Advance from Yorkville, Strengthening Financial Agreement

Rein Therapeutics Files Prospectus Related To Offer And Sale Of Up To 10 Million Shares Of Common Stock By Selling Stockholder- SEC Filing

Rein Therapeutics: Files Prospectus Related to Offer and Sale of up to 10 Mln Shares of Common Stock by Selling Stockholder- SEC Filing

THOMSON REUTERS

Rein Therapeutics Inc. Unveils Innovative Clinical Trial Design for IPF Treatment LTI-03

Rein Therapeutics Shares Lower After Brookline Capital Downgrade

MT Newswires Live

Rein Therapeutics Secures UK Approval to Launch Phase 2 Clinical Trial for Innovative IPF Treatment LTI-03

Rein Therapeutics Inc - to Begin UK Patient Recruitment, Initial Data Expected in 2026

THOMSON REUTERS

Rein Therapeutics Wins U.k. Approval to Launch Phase 2 Clinical Trial of Lti-03 in Idiopathic Pulmonary Fibrosis

THOMSON REUTERS

Brookline Capital Downgrades Rein Therapeutics to Hold From Buy

MT Newswires Live

Rein Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary

Rein Therapeutics Inc. to Present Novel IPF Science and Clinical Insights at IPF Summit 2025

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/RNTX/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"RNTX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"RNTX\",,,,,undefined,":{"symbol":"RNTX","market":"US","secType":"STK","nameCN":"REIN THERAPEUTICS INC","latestPrice":1.32,"timestamp":1760385600000,"preClose":1.3,"halted":0,"volume":61522,"hourTrading":{"tag":"盘后","latestPrice":1.33,"preClose":1.32,"latestTime":"19:39 EDT","volume":521,"amount":699.66,"timestamp":1760398788788},"delay":0,"floatShares":20027700,"shares":24026500,"eps":-2.642829,"marketStatus":"Not Yet Opened","change":0.02,"latestTime":"10-13 16:00:00 EDT","open":1.3,"high":1.345,"low":1.24,"amount":80562.8313686,"amplitude":0.080769,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.642829,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1760428800000},"marketStatusCode":0,"adr":0,"listingDate":1498708800000,"exchange":"NASDAQ","adjPreClose":1.3,"preHourTrading":{"tag":"盘前","latestPrice":1.25,"preClose":1.29,"latestTime":"08:18 EDT","volume":1597,"amount":2040.1500927,"timestamp":1760357908090},"postHourTrading":{"tag":"盘后","latestPrice":1.33,"preClose":1.32,"latestTime":"19:39 EDT","volume":521,"amount":699.66,"timestamp":1760398788788},"volumeRatio":0.339347},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"RNTX\",,,,,undefined,":{"symbol":"RNTX","floatShares":20027700,"roa":"-18.24%","roe":"-79.38%","lyrEps":-3.505399,"volumeRatio":0.339347,"shares":24026500,"dividePrice":0,"high":1.345,"amplitude":0.080769,"preClose":1.3,"low":1.24,"week52Low":1.04,"pbRate":"10.54","week52High":4.4,"institutionHeld":0,"latestPrice":1.32,"eps":-2.642829,"divideRate":0,"volume":61522,"delay":0,"ttmEps":-2.642829,"open":1.3,"prevYearClose":2.3,"prevWeekClose":1.3,"prevMonthClose":1.145,"prevQuarterClose":1.145,"fiveDayClose":1.19,"twentyDayClose":1.11,"sixtyDayClose":1.42},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/RNTX\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-08-14","symbol":"RNTX","fiscalQuarterEnding":"2025/06","expectedEps":-0.22,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1755144000000,"reportTimeType":"post","actualEps":-0.28},{"market":"US","date":"2025-05-15","symbol":"RNTX","fiscalQuarterEnding":"2025/03","expectedEps":-0.21,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1747281600000,"reportTimeType":"post","actualEps":-0.25},{"market":"US","date":"2025-04-07","symbol":"RNTX","fiscalQuarterEnding":"2024/12","expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1743998400000,"reportTimeType":"post","actualEps":-0.26},{"market":"US","date":"2024-11-14","symbol":"RNTX","fiscalQuarterEnding":"2024/09","expectedEps":-0.25,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1731560400000,"reportTimeType":"post","actualEps":-0.27},{"market":"US","date":"2024-08-14","symbol":"RNTX","fiscalQuarterEnding":"2024/06","expectedEps":-0.25,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1723608000000,"reportTimeType":"post","actualEps":-0.45}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"RNTX\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"RNTX\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":0.5,"hold":0.5,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.5,"analysts":2,"updateTime":1758772800000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/RNTX\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"RNTX","date":"2025-10-10","current":-0.499465,"percent":0.639785,"low":-2.000549,"twenty":-1.459659,"median":-0.615534,"eighty":-0.469167,"high":-0.401342,"avg":-0.858088,"sd":0.471706,"marketCap":31927997},"quantilePoints":[{"date":"2025-01-17","current":-1.459659,"twenty":-1.48337,"median":-1.467068,"eighty":-1.447804,"marketCap":42681903},{"date":"2025-01-24","current":-1.630077,"twenty":-1.576729,"median":-1.478183,"eighty":-1.446322,"marketCap":47665070},{"date":"2025-01-31","current":-1.467069,"twenty":-1.741219,"median":-1.496707,"eighty":-1.462623,"marketCap":42898563},{"date":"2025-02-07","current":-1.704171,"twenty":-1.704171,"median":-1.526344,"eighty":-1.459659,"marketCap":49831664},{"date":"2025-02-14","current":-1.741218,"twenty":-1.704171,"median":-1.578211,"eighty":-1.462623,"marketCap":50914961},{"date":"2025-02-21","current":-1.98573,"twenty":-1.794566,"median":-1.630077,"eighty":-1.468551,"marketCap":58064721},{"date":"2025-02-28","current":-1.533754,"twenty":-1.79753,"median":-1.630077,"eighty":-1.47596,"marketCap":44848497},{"date":"2025-03-07","current":-1.467069,"twenty":-1.753073,"median":-1.607848,"eighty":-1.468551,"marketCap":42898563},{"date":"2025-03-14","current":-1.496707,"twenty":-1.741218,"median":-1.552277,"eighty":-1.467069,"marketCap":43765200},{"date":"2025-03-21","current":-1.430022,"twenty":-1.733809,"median":-1.518935,"eighty":-1.461141,"marketCap":41815266},{"date":"2025-03-28","current":-1.311471,"twenty":-1.704171,"median":-1.507821,"eighty":-1.431504,"marketCap":38348715},{"date":"2025-04-04","current":-1.259605,"twenty":-1.704171,"median":-1.496707,"eighty":-1.416685,"marketCap":36832099},{"date":"2025-04-11","current":-0.545587,"twenty":-1.696762,"median":-1.481888,"eighty":-1.32629,"marketCap":34308123},{"date":"2025-04-17","current":-0.577063,"twenty":-1.667124,"median":-1.474478,"eighty":-1.296652,"marketCap":36287438},{"date":"2025-04-25","current":-0.640015,"twenty":-1.630077,"median":-1.467069,"eighty":-1.259605,"marketCap":40246068},{"date":"2025-05-02","current":-0.573565,"twenty":-1.630077,"median":-1.459659,"eighty":-0.64701,"marketCap":36067514},{"date":"2025-05-09","current":-0.601544,"twenty":-1.630077,"median":-1.437431,"eighty":-0.622528,"marketCap":37826905},{"date":"2025-05-16","current":-0.825375,"twenty":-1.622667,"median":-1.430022,"eighty":-0.622528,"marketCap":51902033},{"date":"2025-05-23","current":-0.696336,"twenty":-1.607848,"median":-1.415203,"eighty":-0.629523,"marketCap":42665230},{"date":"2025-05-30","current":-0.696336,"twenty":-1.584138,"median":-1.407793,"eighty":-0.629523,"marketCap":42665230},{"date":"2025-06-06","current":-0.705061,"twenty":-1.560428,"median":-1.311471,"eighty":-0.635119,"marketCap":43199785},{"date":"2025-06-13","current":-0.712292,"twenty":-1.550055,"median":-1.296652,"eighty":-0.639316,"marketCap":43642859},{"date":"2025-06-20","current":-0.592974,"twenty":-1.539682,"median":-1.259605,"eighty":-0.638616,"marketCap":36332127},{"date":"2025-06-27","current":-0.524276,"twenty":-1.524863,"median":-1.24849,"eighty":-0.622528,"marketCap":32122917},{"date":"2025-07-03","current":-0.54597,"twenty":-1.518935,"median":-0.809312,"eighty":-0.609134,"marketCap":33452141},{"date":"2025-07-11","current":-0.535123,"twenty":-1.515971,"median":-0.771713,"eighty":-0.598047,"marketCap":32787529},{"date":"2025-07-18","current":-0.506198,"twenty":-1.508562,"median":-0.726755,"eighty":-0.578462,"marketCap":31015230},{"date":"2025-07-25","current":-0.513429,"twenty":-1.504116,"median":-0.717873,"eighty":-0.562281,"marketCap":31458305},{"date":"2025-08-01","current":-0.421229,"twenty":-1.501152,"median":-0.708677,"eighty":-0.556817,"marketCap":25809102},{"date":"2025-08-08","current":-0.417509,"twenty":-1.496707,"median":-0.703515,"eighty":-0.543648,"marketCap":25581194},{"date":"2025-08-15","current":-0.434435,"twenty":-1.490779,"median":-0.698131,"eighty":-0.532953,"marketCap":26618269},{"date":"2025-08-22","current":-0.445213,"twenty":-1.481888,"median":-0.696336,"eighty":-0.524276,"marketCap":26334772},{"date":"2025-08-29","current":-0.445213,"twenty":-1.478924,"median":-0.689114,"eighty":-0.516321,"marketCap":26334772},{"date":"2025-09-05","current":-0.537801,"twenty":-1.474478,"median":-0.673872,"eighty":-0.514875,"marketCap":31811472},{"date":"2025-09-12","current":-0.425513,"twenty":-1.472996,"median":-0.650825,"eighty":-0.513429,"marketCap":25169516},{"date":"2025-09-19","current":-0.453092,"twenty":-1.467069,"median":-0.643512,"eighty":-0.506198,"marketCap":26800874},{"date":"2025-09-26","current":-0.470822,"twenty":-1.467069,"median":-0.629523,"eighty":-0.496939,"marketCap":27849604},{"date":"2025-10-03","current":-0.457032,"twenty":-1.465587,"median":-0.622528,"eighty":-0.470507,"marketCap":27033925},{"date":"2025-10-10","current":-0.539771,"twenty":-1.459659,"median":-0.615534,"eighty":-0.469167,"marketCap":31927997}],"updateTime":1760423668967},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"RNTX\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2574151142","title":"Rein receives European regulatory approval to initiate Phase 2 trial of LTI-03","url":"https://stock-news.laohu8.com/highlight/detail?id=2574151142","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2574151142?lang=en_us&edition=fundamental","pubTime":"2025-10-09 19:36","pubTimestamp":1760009769,"startTime":"0","endTime":"0","summary":"Rein Therapeutics (RNTX) announced that it has received authorization from the European Medicines Agency, EMA, to initiate the Company’s Phase 2 “R...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/rein-receives-european-regulatory-approval-to-initiate-phase-2-trial-of-lti-03-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/rein-receives-european-regulatory-approval-to-initiate-phase-2-trial-of-lti-03-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","RNTX"],"gpt_icon":0},{"id":"2574590461","title":"Rein Therapeutics receives EMA approval to begin Phase 2 trial of LTI03 for idiopathic pulmonary fibrosis in Europe","url":"https://stock-news.laohu8.com/highlight/detail?id=2574590461","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2574590461?lang=en_us&edition=fundamental","pubTime":"2025-10-09 19:30","pubTimestamp":1760009417,"startTime":"0","endTime":"0","summary":"Rein Therapeutics Inc. has received regulatory approval from the European Medicines Agency  to initiate its Phase 2 \"RENEW\" clinical trial of LTI-03 for the treatment of idiopathic pulmonary fibrosis . The EMA approval covers clinical trial sites in Germany and Poland, adding to previous regulatory clearance from the U.K.'s Medicines and Healthcare products Regulatory Agency . With these authorizations, Rein Therapeutics is set to begin enrolling patients across multiple European regions as part of its global study. There is no indication that this grant or approval was obtained by organizations other than Rein Therapeutics Inc.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rein Therapeutics Inc. published the original content used to","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251009:nNDL37kRYn:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B64PRP62.GBP","LU0314104364.USD","BK4588","LU2210149790.SGD","NDAQ","BK4585","BK4112","IE00BKPKM429.USD","LU2210150020.SGD","RNTX","IE00BGHQF748.EUR","LU2095319765.USD","IE00B3QW5Z07.USD","BK4139"],"gpt_icon":0},{"id":"2574159750","title":"Rein Therapeutics Receives European Regulatory Approval to Initiate Phase 2 Trial of Lti-03 in Idiopathic Pulmonary Fibrosis","url":"https://stock-news.laohu8.com/highlight/detail?id=2574159750","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2574159750?lang=en_us&edition=fundamental","pubTime":"2025-10-09 19:30","pubTimestamp":1760009400,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251009:nTUA9NTV4X:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","RNTX"],"gpt_icon":0},{"id":"2572680190","title":"Rein Therapeutics Inc. Files Initial Statement of Beneficial Ownership by Voss Capital, LP","url":"https://stock-news.laohu8.com/highlight/detail?id=2572680190","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2572680190?lang=en_us&edition=fundamental","pubTime":"2025-10-04 03:10","pubTimestamp":1759518629,"startTime":"0","endTime":"0","summary":"Rein Therapeutics Inc. has filed an initial statement of beneficial ownership  with the U.S. Securities and Exchange Commission. The filing lists Voss Capital, LP as a beneficial owner of more than 10% of the company's outstanding shares. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rein Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on October 03, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251003:nNDL7Q6zHy:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","RNTX"],"gpt_icon":0},{"id":"2569330784","title":"Rein Therapeutics Inc - Receives Communication From FDA on September 16, 2025 - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2569330784","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2569330784?lang=en_us&edition=fundamental","pubTime":"2025-09-22 20:04","pubTimestamp":1758542668,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250922:nFWN3V90GS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RNTX","BK4139"],"gpt_icon":0},{"id":"2569178434","title":"Rein Therapeutics - FDA Recommends Co to Submit Crl Addressing  Amended Study Reports & Justification - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2569178434","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2569178434?lang=en_us&edition=fundamental","pubTime":"2025-09-22 20:04","pubTimestamp":1758542668,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250922:nFWN3V90GS:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","RNTX"],"gpt_icon":0},{"id":"2569783278","title":"Rein Therapeutics Inc. : H.c. Wainwright Initiates Coverage With Buy Rating  and Target Price $10","url":"https://stock-news.laohu8.com/highlight/detail?id=2569783278","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2569783278?lang=en_us&edition=fundamental","pubTime":"2025-09-22 18:07","pubTimestamp":1758535657,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250922:nAZN4K0UN7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RNTX","BK4139"],"gpt_icon":0},{"id":"2568493964","title":"Rein Therapeutics announces publication of data on LTI-03 in IPF","url":"https://stock-news.laohu8.com/highlight/detail?id=2568493964","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2568493964?lang=en_us&edition=fundamental","pubTime":"2025-09-17 19:35","pubTimestamp":1758108919,"startTime":"0","endTime":"0","summary":"Rein Therapeutics (RNTX) announced the publication of novel data on its lead drug candidate, LTI-03, in iScience, a peer-reviewed, open-access jour...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/rein-therapeutics-announces-publication-of-data-on-lti-03-in-ipf-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/rein-therapeutics-announces-publication-of-data-on-lti-03-in-ipf-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["RNTX","LENZ","BK4007","BK4539","BK4139"],"gpt_icon":0},{"id":"2568493277","title":"Rein Therapeutics Announces Publication of New Translational Data in iScience on Company’s Novel Therapy for Idiopathic Pulmonary Fibrosis","url":"https://stock-news.laohu8.com/highlight/detail?id=2568493277","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2568493277?lang=en_us&edition=fundamental","pubTime":"2025-09-17 19:30","pubTimestamp":1758108600,"startTime":"0","endTime":"0","summary":"Peer-reviewed publication highlights potential breakthrough anti-fibrotic properties of LTI-03 in lung tissue from IPF patientsAUSTIN, Texas, Sept.  17, 2025  (GLOBE NEWSWIRE) -- Rein Therapeutics(\"Re","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/09/17/3151534/28652/en/Rein-Therapeutics-Announces-Publication-of-New-Translational-Data-in-iScience-on-Company-s-Novel-Therapy-for-Idiopathic-Pulmonary-Fibrosis.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","BK4139","BK4539","RNTX","BK4007"],"gpt_icon":0},{"id":"2566694771","title":"Rein Therapeutics Secures $1 Million Pre-Paid Advance from Yorkville, Strengthening Financial Agreement","url":"https://stock-news.laohu8.com/highlight/detail?id=2566694771","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2566694771?lang=en_us&edition=fundamental","pubTime":"2025-09-09 20:02","pubTimestamp":1757419356,"startTime":"0","endTime":"0","summary":"Rein Therapeutics Inc. has entered into a new financing agreement with YA II PN, Ltd., a Cayman Islands exempt limited partnership. On the effective date of July 29, 2025, the two parties signed a Pre-Paid Advance Agreement , allowing Rein Therapeutics to request pre-paid advances of up to $6.0 million over a 12-month period. Each advance will be purchased by Yorkville at 95% of its face value, with interest accruing at an annual rate of 8%, or 18% upon default. The agreement also allows Yorkville to require the issuance of common stock to offset outstanding balances under the advances. The initial pre-paid advance of $1.0 million was completed on the effective date, with net proceeds of $0.95 million. A second advance of $1.0 million was completed on September 8, 2025, also yielding net proceeds of $0.95 million.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250909:nNDL6KRp95:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RNTX","BK4139"],"gpt_icon":0},{"id":"2564120433","title":"Rein Therapeutics Files Prospectus Related To Offer And Sale Of Up To 10 Million Shares Of Common Stock By Selling Stockholder- SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2564120433","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2564120433?lang=en_us&edition=fundamental","pubTime":"2025-09-04 06:12","pubTimestamp":1756937533,"startTime":"0","endTime":"0","summary":"Rein Therapeutics Inc ::*REIN THERAPEUTICS: FILES PROSPECTUS RELATED TO OFFER AND SALE OF UP TO 10 MILLION SHARES OF COMMON STOCK BY SELLING STOCKHOLDER- SEC FILING  ((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))  Source Date/Time = 03-SEP-202521:56:33 GMT","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250903:nRSD5qD8HB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","RNTX"],"gpt_icon":0},{"id":"2564314648","title":"Rein Therapeutics: Files Prospectus Related to Offer and Sale of up to 10 Mln Shares of Common Stock by Selling Stockholder- SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2564314648","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2564314648?lang=en_us&edition=fundamental","pubTime":"2025-09-04 05:05","pubTimestamp":1756933530,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250903:nFWN3UQ13J:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","RNTX"],"gpt_icon":0},{"id":"2561406370","title":"Rein Therapeutics Inc. Unveils Innovative Clinical Trial Design for IPF Treatment LTI-03","url":"https://stock-news.laohu8.com/highlight/detail?id=2561406370","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2561406370?lang=en_us&edition=fundamental","pubTime":"2025-08-22 23:40","pubTimestamp":1755877207,"startTime":"0","endTime":"0","summary":"Rein Therapeutics Inc. has presented innovative insights at the IPF Summit 2025, focusing on their novel treatment, LTI-03, which has the potential to reverse the course of Idiopathic Pulmonary Fibrosis . The presentation highlighted LTI-03 as a seven amino acid peptide derived from the Caveolin Scaffolding Domain  of Caveolin-1, known for its regulatory activity affecting a wide range of proteins involved in fibrosis. The peptide is designed to mimic the regulatory functions of Caveolin-1 and can enter cells to act at the cell membrane and intracellularly. Studies have shown that LTI-03, administered via dry powder inhaler directly to the lungs, remains intact in the lungs 24 hours after administration. You can access the full presentation through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes o","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250822:nNDL7m4XVw:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RNTX","BK4139"],"gpt_icon":0},{"id":"2560111147","title":"Rein Therapeutics Shares Lower After Brookline Capital Downgrade","url":"https://stock-news.laohu8.com/highlight/detail?id=2560111147","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2560111147?lang=en_us&edition=fundamental","pubTime":"2025-08-20 03:03","pubTimestamp":1755630224,"startTime":"0","endTime":"0","summary":"Rein Therapeutics (RNTX) shares fell 6.2% in recent Tuesday trading after Brookline Capital downgraded the stock to hold from buy.Trading volume stood at over 54,901 shares, versus the daily average of 42,806.Price: 1.06, Change: -0.07, Percent Change: -6.19","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BRKL","LENZ","RNTX"],"gpt_icon":0},{"id":"2560719697","title":"Rein Therapeutics Secures UK Approval to Launch Phase 2 Clinical Trial for Innovative IPF Treatment LTI-03","url":"https://stock-news.laohu8.com/highlight/detail?id=2560719697","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2560719697?lang=en_us&edition=fundamental","pubTime":"2025-08-19 20:00","pubTimestamp":1755604833,"startTime":"0","endTime":"0","summary":"Rein Therapeutics Inc. has announced that the UK Medicines and Healthcare products Regulatory Agency  has given approval to launch a Phase 2 clinical trial for its lead drug candidate, LTI-03, targeting idiopathic pulmonary fibrosis . The trial, named \"RENEW,\" will enroll up to 120 patients worldwide to evaluate two dose groups of LTI-03 against a placebo. The primary aim is to assess safety and tolerability over a 24-week treatment period, with secondary endpoints focusing on lung function and imaging-based assessments of fibrosis progression. Patient recruitment is expected to start soon in the UK, with initial data anticipated in 2026. Results from the trial have not yet been presented.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250819:nNDL1SPpCL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","LU2210149790.SGD","IE00BKPKM429.USD","LU2210150020.SGD","IE00B3QW5Z07.USD","BK4112","BK4585","LU0314104364.USD","RNTX","LU2095319765.USD","BK4139","IE00BGHQF748.EUR","NDAQ","IE00B64PRP62.GBP"],"gpt_icon":0},{"id":"2560961121","title":"Rein Therapeutics Inc - to Begin UK Patient Recruitment, Initial Data Expected in 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2560961121","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2560961121?lang=en_us&edition=fundamental","pubTime":"2025-08-19 20:00","pubTimestamp":1755604801,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250819:nTUA6S3PSZ:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RNTX","BK4139"],"gpt_icon":0},{"id":"2560519695","title":"Rein Therapeutics Wins U.k. Approval to Launch Phase 2 Clinical Trial of Lti-03 in Idiopathic Pulmonary Fibrosis","url":"https://stock-news.laohu8.com/highlight/detail?id=2560519695","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2560519695?lang=en_us&edition=fundamental","pubTime":"2025-08-19 20:00","pubTimestamp":1755604801,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250819:nTUA6S3PSZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","RNTX"],"gpt_icon":0},{"id":"2560193789","title":"Brookline Capital Downgrades Rein Therapeutics to Hold From Buy","url":"https://stock-news.laohu8.com/highlight/detail?id=2560193789","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2560193789?lang=en_us&edition=fundamental","pubTime":"2025-08-19 19:18","pubTimestamp":1755602339,"startTime":"0","endTime":"0","summary":"Brookline Capital Downgrades Rein Therapeutics to Hold From Buy","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["RNTX","LENZ","BRKL"],"gpt_icon":0},{"id":"2559607569","title":"Rein Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2559607569","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2559607569?lang=en_us&edition=fundamental","pubTime":"2025-08-15 07:37","pubTimestamp":1755214679,"startTime":"0","endTime":"0","summary":"Rein Therapeutics Inc reports results for the quarter ended June 30 - Earnings SummaryRein Therapeutics Inc RNTX.OQ reported a quarterly adjusted loss of 28 cents per share for the quarter ended June ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250814:nL8N3U61YZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RNTX"],"gpt_icon":0},{"id":"2559616962","title":"Rein Therapeutics Inc. to Present Novel IPF Science and Clinical Insights at IPF Summit 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2559616962","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2559616962?lang=en_us&edition=fundamental","pubTime":"2025-08-15 05:00","pubTimestamp":1755205241,"startTime":"0","endTime":"0","summary":"Rein Therapeutics Inc. , a biopharmaceutical company focused on orphan pulmonary and fibrosis indications, will be presenting at the IPF Summit 2025, scheduled for August 19-21, 2025, in Boston, MA. Chief Scientific Officer Cory Hogaboam will discuss the role of lung-resident macrophages in idiopathic pulmonary fibrosis  and the potential of Caveolin-scaffolding domain  peptides in repairing lung tissue. Additionally, Chief Executive Officer Brian Windsor will provide insights into the Phase 2 trial design of LTI-03, focusing on trial feasibility and patient recruitment strategies.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rein Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire  on ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250814:nNDL34WNvk:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210149790.SGD","BK4588","RNTX","IE00BGHQF748.EUR","BK4585","IE00B3QW5Z07.USD","BK4139","IE00BKPKM429.USD","LU2210150020.SGD","LU0314104364.USD","IE00B64PRP62.GBP","LU2095319765.USD","NDAQ","BK4112"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":36,"code":"91000000","status":"200"}]}}